HK inno.N Corporation (KOSDAQ:195940)

South Korea · Delayed Price · Currency is KRW

45,550

-6,850 (-13.07%)

At close: Mar 4, 2026

26.53% (1Y)

Market Cap	1.48T
Revenue (ttm)	839.63B
Net Income (ttm)	41.49B
Shares Out	28.33M
EPS (ttm)	1,451.65
PE Ratio	36.10
Forward PE	16.58
Dividend	350.00 (0.65%)
Ex-Dividend Date	n/a

Volume	386,460
Average Volume	240,844
Open	50,500
Previous Close	52,400
Day's Range	45,450 - 51,000
52-Week Range	31,650 - 58,600
Beta	0.68
RSI	29.62
Earnings Date	Feb 11, 2026

About HK inno.N

HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, no... [Read more]

Industry Medical Care Facilities

Sector Healthcare

Founded 1984

Employees 1,695

Stock Exchange KOSDAQ

Ticker Symbol 195940

Full Company Profile

Financial Performance

In 2021, HK inno.N's revenue was 769.79 billion, an increase of 28.63% compared to the previous year's 598.45 billion. Earnings were 21.35 billion, a decrease of -23.49%.

Financial Statements

News

There is no news available yet.